Article Text
Abstract
Background Acute ischemic stroke (AIS) due to intracranial atherosclerotic disease (ICAD) can be challenging to treat. Novel technical approaches, such as the Onyx Frontier™ stent (Medtronic, Santa Rosa, CA), are emerging. The aim of our multicenter study is to present our initial experience with the Onyx Frontier™ balloon-mounted drug-eluting stent for AIS due to ICAD.
Methods We conducted a multicenter retrospective case series describing the technical feasibility and performance of using the Onyx Frontier™ balloon-mounted drug-eluting stent in patients with AIS due to ICAD across three comprehensive stroke centers in the United States.
Results We included 23 patients in our study (mean age 67.3 [10.7]; females: n=13/23, 56.5%). The majority of patients were African American/Black (n=14/23, 60.9%). The most common site of vessel occlusion was the M1 branch of the middle cerebral artery (MCA) (n=14/23, 60.9%), followed by the vertebrobasilar system (n=5/23, 21.7%), and the internal carotid artery (n=3/23, 13.0%). There was a single case of M2 MCA occlusion. All stent embolization procedures were successfully treated with the Onyx Frontier™ zotarolimus-eluting stent. None of the patients had any restenosis or re-treatment. All cases required a single stent except for one, where two were implanted. Transfemoral access was used in most cases (n=18/23, 78.3%), with one in-hospital death due to access site complication (n=1/23, 4.3%).
Conclusions This is the largest multicenter case series demonstrating the feasibility and safety of using the Onyx Frontier™ balloon-mounted zotarolimus-eluting stent to treat symptomatic AIS due to ICAD.
Disclosures A Chahine: None.